Navignostics

Navignostics is a subsidiary of the University of Zurich, established in April 2022. The company utilizes spatial single-cell proteomics to perform advanced analysis on tumor samples. As a startup active in the field of personalized medicine, Navignostics is committed to providing innovative solutions to determine the optimal treatment strategy for each cancer patient. Additionally, Navignostics offers advanced services to pharmaceutical companies to accelerate the development of cancer drugs and contribute to the development of companion diagnostics.